NLM logo
National Information Center on Health Services Research and Health Care Technology (NICHSR)

HSRProj (Health Services Research Projects in Progress)

Information about ongoing health services research and public health projects

Anti-tumor necrosis factor (TNF) monotherapy versus combination therapy with low-dose methotrexate in pediatric Crohn's disease
Investigator (PI): Kappelman, Michael
Performing Organization (PO): (Current): University of North Carolina at Chapel Hill, School of Medicine, Department of Pediatrics, Division of Pediatric Gastroenterology / (919) 966-2435
Supporting Agency (SA): Patient-Centered Outcomes Research Institute (PCORI)
Initial Year: 2015
Final Year: 2021
Record Source/Award ID: PCORI/PCS-1406-18643
Funding: Total Award Amount: $7,909,644
Award Type: Contract
Award Information: PCORI: More information and project results (when completed)
Abstract: Crohn's disease (CD), which affects about 600,000 Americans, causes abdominal pain and bloody diarrhea, leading to frequent hospitalizations, surgery, and decreased quality of life. Pediatric CD (PCD) affects about 38,000 children, is often progressive, and can impair both physical and emotional development. PCD treatment usually includes corticosteroids, anti-inflammatory aminosalicylates, immunosuppressives, or drugs that target tumor necrosis factor (TNF). We will conduct a large, pragmatic clinical trial to determine whether an intervention using an anti-TNF drug plus low-dose oral methotrexate is more effective than anti-TNF therapy alone among children with moderate-to-severe PCD who have not previously had anti-TNF therapy. Our specific aims are to (1) determine whether methotrexate, in combination with anti-TNF therapy, is more effective than anti-TNF therapy alone in the induction and subsequent maintenance of remission for 2 years; (2) compare patient-reported outcomes; (3) describe investigator-reported adverse events; and (4) collect blood serum from trial participants to facilitate future studies evaluating anti-TNF concentrations and antibody formation. Participants, recruited through the Improve Care Now (ICN) Learning Health System, will be less than 18 years old, have moderate-to-severe PCD, and be just beginning anti-TNF therapy. Participants will be randomly assigned to receive either anti-TNF therapy and oral methotrexate (combination therapy) or anti-TNF monotherapy alone; they will be followed for two years. The primary measure of effectiveness will be achieving and maintaining a symptom-free remission, without the need for steroids, hospitalization, or surgery. In addition, we will identify and prioritize a set of patient-reported outcomes that will be used as another measure of effectiveness. Finally, we will compare the occurrence of moderate or severe treatment-related side effects. We engaged clinicians in the planning of this trial and have partnered with the Crohn's and Colitis Foundation of America (CCFA), the nation's leading inflammatory bowel disease advocacy organization, as well as children's hospitals, payers, and pharmaceutical companies. An advisory board of patients, parents, the CCFA, industry, payers, and health system leaders will meet with the investigators twice yearly to review study progress, troubleshoot as needed, and help plan dissemination strategies. This study will have substantial impact on patient decision making, care, and outcomes. Conducting this trial within ICN will allow the same network that generates the research to implement evidence into practice.
MeSH Terms:
  • Administration, Oral
  • Child
  • Crohn Disease /*drug therapy
  • Humans
  • Methotrexate /*administration & dosage
  • Outcome Assessment (Health Care)
  • Program Evaluation
  • Quality of Life
  • Remission Induction
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha /*antagonists & inhibitors
  • /blood
  • United States
Country: United States
State: North Carolina
Zip Code: 27599
UI: 20153605
Project Status: Ongoing
Record History: ('2017: Project extended to 2021.',)